Latest deal DXB negotiated +30% royalties. Yes +30% which is phenomenal. So now we have 2 independent parties thoroughly reviewed the clinical data and said yes and more deals to come. Now getting back to that +30% royalties obvious to me DXB huge cash pile upfront payments not their main objective in future deals but maximizing the return on each drug sale very exciting times ahead.
DXB - Research & Valuation, page-74
-
- There are more pages in this discussion • 157 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
-0.015(2.68%) |
Mkt cap ! $308.1M | |||
| Open | High | Low | Value | Volume |
| 55.5¢ | 57.5¢ | 53.5¢ | $1.264M | 2.296M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 51088 | 54.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.0¢ | 24252 | 5 |
View Market Depth
| Last trade - 13.31pm 22/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |